CJC-1295 / Ipamorelin (No DAC)
$50.00
CJC-1295 / Ipamorelin (No DAC)
CJC-1295 (No DAC) + Ipamorelin
CJC-1295/Ipamorelin (No DAC) — the lean mass layer of the Clav stack. GHRH + GHRP synergy for pulsatile GH release. Preserves lean tissue during aggressive fat loss.
For research purposes only. Not intended for human use.
Dual GH Secretagogue: GHRH-R + GHS-R1a (Ghrelin Receptor)
CJC-1295 No DAC is a GHRH analog (also known as Mod GRF 1-29) that binds GHRH receptors on anterior pituitary somatotrophs, stimulating GH release with ~30 minute half-life — preserving pulsatile GH patterns. Ipamorelin (CAS: 170851-70-4) selectively activates GHS-R1a (ghrelin receptor) through a different G-protein pathway. Dual-receptor activation is additive: combined GH release substantially exceeds either compound alone. Ipamorelin does not elevate cortisol, prolactin, or ACTH at research doses — unlike GHRP-2 or GHRP-6.
Lean Mass Preservation During Fat Loss
Retatrutide produces significant fat loss, which in aggressive caloric deficits can include lean mass loss. CJC-1295/Ipamorelin research investigates whether GH secretagogue co-administration preserves lean tissue during GLP-driven protocols. GH and IGF-1 elevation has well-established anabolic effects on muscle protein synthesis.
Pulsatile GH Release (No DAC)
The No DAC formulation preserves natural pulsatile GH secretion — physiologically important for GH's anabolic effects. DAC-modified CJC-1295 produces continuous GH elevation that blunts natural pulsatility. No DAC is specifically chosen for protocols requiring physiological GH patterns.
Ipamorelin Selectivity
Unlike GHRP-2 and GHRP-6, Ipamorelin activates GHS-R1a with high selectivity — without significant cortisol, ACTH, or prolactin elevation. This selectivity makes it the preferred ghrelin receptor agonist for clean GH secretagogue research.
Specifications
Research FAQ
Why add CJC-1295/Ipamorelin to a Retatrutide protocol?
GLP peptides at research doses produce lean mass loss alongside fat loss. CJC-1295/Ipamorelin provides pulsatile GH elevation that supports lean tissue preservation during caloric restriction — the lean mass layer of the Clav stack.
When should CJC-1295/Ipamorelin be administered?
Pre-sleep timing maximizes the natural nocturnal GH pulse — approximately 70% of daily GH secretion occurs during slow-wave sleep. CJC-1295/Ipamorelin amplifies this pulse when administered 30-60 minutes before sleep.
